NeuroSense Therapeutics, Ltd. (NRSN) - היקף יתרות המזומנים של החברה

NeuroSense Therapeutics (NRSN) is developing innovative treatments for Parkinson's disease and ALS, which forms its primary growth potential. The company's cash balance on the GURU.Markets chart confirms this trajectory, with the metric value standing at 0.00. Stability is ensured by transparent grant control provided by academic management and the effective delegation of clinical trials to a pool of reliable international contractors.
פילוחים אנליטיים של חברת NeuroSense Therapeutics

To identify the fundamental drivers of stability for NeuroSense Therapeutics (NRSN), liquidity analysis is key, where the current size of cash assets records the cash balance at the end of the trading day as a balance between capital inflows and outflows. This indicator determines the company's ability to fund high-cost thermotransportation of biomaterials for clinical trials, preventing the risk of development halts due to a deficit of operational resources.